阿柔比星联合中剂量阿糖胞苷诱导治疗难治和复发性急性髓样白血病的疗效

Efficacy of aclacinomycin plus intermediate dose of cytarabine for patients with refractory and relapsed acute myeloid leukemia

目的:探讨阿柔比星(aclacinomycin,Acla)联合中剂量阿糖胞苷(intermediate-dose cytarabine,IDAra-C)治疗难治和复发性急性髓样白血病(acute myeloid leukemia,AML)的疗效和不良反应。方法:26例难治和复发性AML患者接受Acla联合IDAra-C方案进行解救治疗,评估不良反应和疗效。结果:26例患者接受2个周期Acla联合IDAra-C方案的化疗后,12例完全缓解,7例部分缓解,7例无缓解,1例因治疗过程中发生严重感染而死亡。结论:Acla联合IDAra-C方案可作为难治和复发性AML再诱导治疗的一种选择,患者大多耐受良好。

Objective ： To observe the efficacy and safety of aclacinomycin （Acla） plus intermedium-dose cytarabine （ ID Ara-C） （AA regimen） on patients with refractory and relapsed acute myeloid leukemia （AML）. Methods：Twenty-six patients with refractory and relapsed AML received rescue therapy with AA regimen. The clinical outcome and adverse reaction were evaluated. Results：After 2 cycyles of rescue therapy with AA regimen, 12 cases achieved complete response （CR）, 7 cases achieved partial response （PR）, and 7 patients had no response. One was dead because of severe infection. Conclusion ： AA regimen is effective in the treatment of refractory and relapsed AML. Most patients are well tolerated.